TheProfitWatch

AGEN - Agenus Inc.

Day 1m 10m 60m PreMarket Market AfterHours Gap
4.16 0.08 (1.92%) --- 0.0 (0.0%) 0.02 (0.47%) 0.14 (3.37%) -0.03 (-0.7%) 0.0 (0.0%) -0.07 (-1.6%)

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Category: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Market Period: Market

Earnings & Ratios

Basic EPS:
-1.0
Diluted EPS:
-1.0
Basic P/E:
-4.24
Diluted P/E:
-4.24
RSI(14) 1m:
80.3
VWAP:
4.24
RVol:

Events

Period Kind Movement Occurred At

Related News